CAMBRIDGE, United Kingdom, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Mestag Therapeutics (“Mestag”), a biotech company harnessing new insights into fibroblast-immune...
With most of Evaxion’s strategic milestones for 2024 now successfully achieved, the company announces milestones for 2025The 2025 key milestones...
ANNOUNCEMENT NO. 287 9 December 2024 Major shareholder announcement Major shareholder announcement – AIM International Mutual Funds Pursuant to...
ANNOUNCEMENT NO. 286 9 December 2024 Major shareholder announcement Major shareholder announcement – Invesco Ltd. Pursuant to Section 30...
Preliminary data suggests improved relapse-free survival compared to published groups of acute myeloid leukemia (AML) patients at high risk of...
Breakthrough Innovation for the Purification of mRNA Therapeutics and VaccinesWALTHAM, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN),...
No dose-limiting toxicities reported in two different weekly doses in heavily pre-treated patients Preliminary evidence of dose response includes significant...
Topline data from ATTENTION-AD Open-Label-Extension (OLE) 96/144-Week trial J.P. Morgan 2025 Healthcare Conference, taking place January 13–16, 2025, in San...
Relmada Therapeutics has Commenced a Process to Explore Strategic Alternatives to Maximize Shareholder ValueCORAL GABLES, Fla., Dec. 09, 2024 (GLOBE...
ST. LOUIS and SHANGHAI, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS) and Shanghai MicroPort EP Medtech Co., Ltd....
AIV001 is currently in development for evaluation in Superficial and Nodular Superficial Basal Cell Carcinoma (sBCC and nBCC) COSA MESA,...
PRESS RELEASE EnnoDC presents preliminary data for immunotherapy candidate CD40.HVac in HPV+ oropharyngeal cancer at ESMO IO 2024 Paris, France,...
CRB-601 is an anti-αvβ8 monoclonal antibody designed to block activation of latent TGFβ in the tumor micro-environmentNORWOOD, Mass., Dec. 09,...
Data demonstrate dose dependent survival advantage with AUTX-703 in primary patient-derived orthotopic AML model IND submissions on track for late...
BURLINGTON, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused...
– Interim analysis from Phase 1a portion of KOMET-007 shows 100% CR rate in NPM1-m and 83% CR rate in...
Phase 1 clinical trial for OP-3136 to initiate in early 2025 SAN FRANCISCO, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Olema...
Data from the Phase 2 PRIMO trial in 123 patients showed an overall response rate (ORR) of 48%, a complete...
56% mean improvement in Total Symptom Score (TSS) at 24 weeks with 76% of patients achieving at least a 50%...
Dr. Alison Moskowitz presented results of a Phase 1 study of combination duvelisib plus ruxolitinib in relapsed/refractory (R/R) peripheral T-cell...